Literature DB >> 24716844

Novel anti-malarial combinations and their toxicity.

Brian Angus1.   

Abstract

Artemisinin combination therapy for the treatment of uncomplicated malaria includes artemether plus lumefantrine, artesunate plus amodiaquine, artesunate plus mefloquine, artesunate plus sulfadoxine-pyrimethamine and dihydroartemisinin plus piperaquine. These drugs are safe and efficacious at present. The emergence of artemisinin resistant parasites in SE Asia means that there is a need to optimise drug dosing and investigate novel therapies to maintain the impressive reduction in malaria mortality which has been seen in the past decade.

Entities:  

Mesh：

Substances：

Year:  2014        PMID： 24716844     DOI： 10.1586/17512433.2014.907523

Source DB:  PubMed          Journal:  Expert Rev Clin Pharmacol        ISSN： 1751-2433            Impact factor:   5.045


  9 in total

1.  Effects of dihydroartemisinin combined with cisplatin on proliferation, apoptosis and migration of HepG2 cells.

Authors:  Qi Rao; Ruochan Li; He Yu; Lei Xiang; Bin He; Fenghua Wu; Gang Zhao
Journal:  Oncol Lett       Date:  2022-06-22       Impact factor: 3.111

Review 2.  Psychiatric effects of malaria and anti-malarial drugs: historical and modern perspectives.

Authors:  Remington L Nevin; Ashley M Croft
Journal:  Malar J       Date:  2016-06-22       Impact factor: 2.979

3.  A dietary strategy for the management of artemether-lumefantrine-induced cardiovascular and renal toxicity.

Authors:  Isaac Julius Asiedu-Gyekye; Mahmood Abdulai Seidu; Banga Benoit N'guessan; Samuel Frimpong-Manso; Joseph Edusei Sarkodie; Samuel Adjei; Schevadnazy Kutu; Joseph Osei-Little; Alexander Kwadwo Nyarko; Philip Debrah
Journal:  BMC Complement Altern Med       Date:  2016-09-06       Impact factor: 3.659

4.  Artemether-lumefantrine and liver enzyme abnormalities in non-severe Plasmodium falciparum malaria in returned travellers: a retrospective comparative study with quinine-doxycycline in a Portuguese centre.

Authors:  André Silva-Pinto; Rogério Ruas; Francisco Almeida; Raquel Duro; André Silva; Cândida Abreu; António Sarmento
Journal:  Malar J       Date:  2017-01-25       Impact factor: 2.979

5.  Comparative analysis of the safety and tolerability of fixed-dose artesunate/amodiaquine versus artemether/lumefantrine combinations for uncomplicated falciparum malaria in pregnancy: a randomized open label study.

Authors:  Osede I Iribhogbe; Igue Emmanuel; Marylove Odianosen
Journal:  Clin Pharmacol       Date:  2017-05-09

6.  A Novel Single-Nucleotide Polymorphism Loop Mediated Isothermal Amplification Assay for Detection of Artemisinin-Resistant Plasmodium falciparum Malaria.

Authors:  Abu Naser Mohon; Didier Menard; Mohammad Shafiul Alam; Kevin Perera; Dylan R Pillai
Journal:  Open Forum Infect Dis       Date:  2018-01-09       Impact factor: 3.835

7.  Optimal 10-Aminoartemisinins With Potent Transmission-Blocking Capabilities for New Artemisinin Combination Therapies-Activities Against Blood Stage P. falciparum Including PfKI3 C580Y Mutants and Liver Stage P. berghei Parasites.

Authors:  Ho Ning Wong; Vivian Padín-Irizarry; Mariëtte E van der Watt; Janette Reader; Wilna Liebenberg; Lubbe Wiesner; Peter Smith; Korina Eribez; Elizabeth A Winzeler; Dennis E Kyle; Lyn-Marie Birkholtz; Dina Coertzen; Richard K Haynes
Journal:  Front Chem       Date:  2020-01-10       Impact factor: 5.221

8.  Xylopic acid-amodiaquine and xylopic acid-artesunate combinations are effective in managing malaria in Plasmodium berghei-infected mice.

Authors:  Silas Acheampong Osei; Robert Peter Biney; Ernest Obese; Mary Atta-Panyi Agbenyeku; Isaac Yaw Attah; Elvis Ofori Ameyaw; Johnson Nyarko Boampong
Journal:  Malar J       Date:  2021-02-25       Impact factor: 2.979

9.  Investigating the Comparative Effects of Six Artemisinin-based Combination Therapies on Plasmodium-induced Hepatorenal Toxicity.

Authors:  Innocent A Edagha; Arit J Ekpo; Edelungudi I Edagha; Joy V Bassey; Titus P Nyong; Anthony S Akpan; Rose F Obeten; Anthony S Okon; Blessing A Ating
Journal:  Niger Med J       Date:  2019-11-25
  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.